Gene regulatory network and signalling pathway rewiring: How blood cancer cells shift their shapes to evade drug treatment (IMAGE)
Caption
Figure 1: The RUNX1/AP-1 axis operates differently in different types of AML. Cytokine receptors are indicated in different colours with their ligand shown as coloured round shapes on the cell surface. Transcription factors such as JUN and FOS are indicated as elliptical shapes with the DNA binding domains depicted lines below the shape. Gene names are in italics. Asterisks depict phosphorylated proteins. FLT3i, RASi, VEGFi and IL-5i are inhibitors of the respective signalling pathways. RUNX/CBFβi and dnFOS inhibit RUNX1 and AP-1 DNA binding, respectively. The mutant DNA binding domain in dnFOS blocks JUN family members from binding and is shown as a red elliptical shape. Arrows indicate activation, inhibitory action is indicated by a red bar. (A) Interplay between signalling and the RUNX1/ AP-1 axis in FLT3-ITD AML. (B) Interplay between signalling and the RUNX1/AP-1 axis in t(8;21) AML. The RUNX1-ETO fusion protein consists of the RUNX1 DNA binding domain fused to the ETO (RUNX1T1) protein is indication by two shapes fused together.
Credit
2024 Bonifer and Cockerill
Usage Restrictions
Original content
License
Original content